This is the first study aiming to determine the therapeutic effects of the Sambucus ebulus aquatic extract as an antileishmanial herbal drug and evaluate the immune 
| INTRODUC TI ON
Leishmania parasites are the causative agents of leishmaniasis, a group of protozoan infection transmitted by a bite of female sand flies to human. Leishmaniasis is the world's most devastating neglected tropical disease (NTD) with a complicated ecology [1] [2] [3] whose transmission needs parasites, vectors, reservoirs and human interactions. 4, 5 Leishmaniasis is an important endemic disease across the five continents which involve 98 countries, especially the developing countries. 4 Based on World Health Organization (WHO) reports, nearly 12 million people are affected and 350 million individuals are at risk of the disease. [5] [6] [7] Leishmania infection has been clinically categorized into three major forms: visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL). 1, 8 Globally, CL is the most prevalent form of the disease with approximately 1.2 million new cases diagnosed each year, where 90% of cases occur in seven developing countries including Afghanistan, Iran, Algeria, Peru, Brazil, Saudi Arabia and Syria. 9, 10 Although different chemical compounds are available for the treatment of various clinical forms of leishmaniasis, there is no effective treatment against the disease and the current chemical therapies suffer many critical disadvantages. 11 The usual and common treatment of leishmaniasis is the prescription of pentavalent antimony (antimonials) including Pentostam (sodium stibogluconate)
or Glucantime (meglumine antimoniate) which have remained the first-line chemical drugs against leishmaniasis globally. 12, 13 Another alternative first-line treatment is antifungal drug amphotericin B (AMB) which is used in the case of resistance to the antimony treatment. 1, 14, 15 Recently, new chemical therapeutic alternatives have been recommended for the treatment of leishmaniasis including lipid-associated AMB, paromomycin, miltefosine, sitamaquine, azoles and itraconazole. 1, 13 All of the mentioned antileishmanial drugs have many shortcomings due to their negative side effects as well as the persistence of Leishmania infection because of host immunity and the ability of the parasite to modify the host immune responses. 13, 16 Although the recommended antileishmanial drugs such as antimonials can stimulate the host immune responses and resolve the Leishmania infection, several documented studies have described the insufficient antileishmanial activity and their different adverse effects which can culminate in treatment failure. Hence, discovering novel compounds with lower toxicity, high immunomodulatory effects and antileishmanial activity is vital. 16 To date, use of natural product has been one of the main effective choices in the treatment of parasitic diseases including leishmaniasis. Studies have suggested that a natural herbal compound does not have a high probability of causing adverse effects. They are sustainable, economical, available and more importantly have immunomodulatory effects compared with common antileishmanial compounds. 16, 17 These herbal extracts can be utilized as alternative natural treatments for cancers and serious infectious diseases such as CL, in which the host immune responses are critical for evolution of the disease. 9, 16, 18 In traditional medicine, one of the less studied herbal plants for its antiparasitic characteristics is Sambucus ebulus L. (S ebulus), known as dwarf elder or elderberry, 19, 20 which is ubiquitously present in different parts of Iran. 21 S ebulus plant is known as Khamaan in Iranian (Persian) traditional medicine which is prescribed as a natural herbal remedy in several diseases and various painful conditions such as sore throat, arthritis, honey bee bites and haemorrhoid. 19, 21 Further, this herbal plant has lately shown to have anti-Helicobacter pylori activity, antitumour, antinociceptive, anti-inflammatory, antiangiogenic and anti-oxidative activities. [20] [21] [22] [23] [24] Previous studies have revealed that S ebulus has different active compounds including glycosides flavonoids, tannins, steroids, colchicine, ebulitins, anthocyanins, caffeic acids and volatile substances. 20, 21 The compounds such as flavonoids can trigger the host immune responses. 20 To the best of our knowledge, this is the first comprehensive study measuring the major efficacy, safety, toxicity and antiparasitic prosperities of S ebulus aqueous extract against L major in both in vitro and in vivo situations and evaluating the immune responses in mice model of cutaneous leishmaniasis.
| MATERIAL S AND ME THODS

| Chemicals and reagents
Phorbol 12-myristate 13-acetate (PMA) and 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were obtained from SigmaAldrich (Deisenhofen, Germany). Schneider's Drosophila medium, M199 medium, Dulbecco's modified Eagle's medium (DMEM) phenol redfree, RPMI-1640, foetal calf sera (FCS), dimethylsulphoxide (DMSO), gentamicin, L-glutamine, adenosine, HEPES, hemin and amphotericin B (AMB) were purchased from Gibco (Gibco, Life Technologies GmbH, Karlsruhe, Germany) and Sigma (Darmstadt, Germany). Herbarium Center. The S ebulus material was dried at room temperature and coarsely grounded and powdered using a mixer and then kept in a dark amber-coloured bottle before herbal extraction.
| Plant material
| Herbal extraction
The aqueous extraction processes of powdered materials of S ebulus were applied according to the method as described previously. 25 It was sterilized by filtration via a membrane filter (0.22 μm). The extract utilized freshly to prepare for different concentrations for evaluation of its antileishmanial activity.
| Cells culture
Human monocyte cell line called THP1 (ATCC ® TIB-202 TM) was used in this study. They were cultured in RPMI-1640 supplemented with FCS 10% at a temperature of 37°C in a CO 2 5% incubator. To form differentiated and adherent macrophages, they were counted and treated with 5 μg/mL of PMA. Nonadherent macrophage cells were eliminated by washing twice with RPMI 1640 medium. THP1 cells treated with PMA were utilized for further evaluations.
26,27
| Extract cytotoxicity evaluations on macrophages
The cytotoxicity effects of S ebulus extract were assessed via culti- with free access to tap water and enough rodent food.
| Promastigotes extract susceptibility assay
| General safety assessment of S. ebulus extract in BALB/c mice
The toxicity of the S ebulus extract was assessed in susceptible BALB/c mice with the age of 6-8 weeks weighing nearly 20 g. Seven groups (four mice per group) are chosen and nominated as G A to G F as presented in Table 1 
| Parasite and inoculation of mice
The pathogenic Iranian strain of L major (MRHO/IR/75/ER) was used in the current experiment. The parasite was maintained in a virulent state by a continuous passage in BALB/c mice. Isolated lymph nodes (LNs) from infected mice were cultured at 26°C in M199 medium at pH 7.4, supplemented with FCS 5% and gentamicin 50 μg/mL.
The promastigotes of the parasite were subcultured and monitored daily. A total of 2 × 10 6 stationary phase metacyclic promastigotes (4-5 days) isolated by Ficoll 400 was injected subcutaneously (SC) in their right hind footpad. 32 Frozen and thawed (F/T) antigen preparation of L major parasite has been described in our previous study.
32,33
| Schedule of animal study
For the infected mice, nine groups (n = 15 mice per each group) were used in the following way: G1: infected group with no treatment as control; G2: infected group treated with the standard antileishmanial drug, amphotericin B (AMB) 8 mg/kg; G3: infected group treated with PBS 1X; G4, G5 and G6 infected groups treated with S ebulus 100, 150 and 200 mg/kg, respectively, administrated by IM route;
and G7, G8 and G9 infected groups treated with S ebulus 100, 150
and 200 mg/kg, respectively, administrated by IL route (Table 2) .
Four weeks post infection, G2 received AMB intraperitoneally (IP) During the entire infection/treatment course, footpad swelling was monitored weekly and recorded for each mouse separately.
The increase in the thickness and width of the infected and uninfected footpads was measured by a metric caliper. After 14 days of AMB treatment and 1 month of S ebulus treatment, five mice from each group were sacrificed. Then, their infected lymph nodes (LNs), spleens and footpads were isolated and evaluated for parasite load, cytokine levels and arginase activity.
| Quantification of parasite burden using limiting dilution assay
Eight weeks after infection, five mice from each group were sacrificed and the motile promastigotes of Leishmania in the drained LNs were counted microscopically. Also, the parasite burden was quantified by limiting dilution assay as previously described. DNA was used in eightfold dilutions corresponding to 1 × 10 7 parasites to draw the standard curve using Applied Biosystem 7500 realtime PCR. 32, 35 All of the reactions were done in duplicate.
| Cytokine production by splenocytes in mice
IL-4 and IFN-γ productions were measured in the supernatant of splenocytes as described elsewhere. 32, 33 Briefly, at the end of the treatment (8 weeks after infection), five mice from each group were sacrificed with the spleen of each mouse homogenized using DMEM phenol red-free medium supplemented with inactivated FCS 5%. All experiments were done in triplicate.
| Determination of arginase activity
Four weeks after the treatment, the enzymatic activity of arginase (ARG) was assessed in the footpads of sacrificed mice. It measures the conversion of L-arginine to L-ornithine through the microplate method which has been described elsewhere. [36] [37] [38] Briefly, cell suspensions of isolated footpads were homogenate in 500 μL of PBS 1X. The suspensions were centrifuged for 5 minutes at 500 g, and cell-free supernatants were centrifuged at 12 000 g for 10 min- 
| Statistical analysis
CC 50 , ED 50 and IC 50 calculations and statistical analyses were conducted using Prism 6.0 for Windows (GraphPad Prism, San Diego, CA).
The differences were analysed by one-way ANOVA and Student's t test.
The P-values less than 0.05 were considered statistically significant.
| RE SULTS
| Cytotoxicity evaluation
As demonstrated in Figure 1 , the results of colorimetric MTT assay indicated that S ebulus aqueous extract did not exert any toxic effects to the PMA-treated human THP1 macrophages, even at its higher concentrations (125-64 000 μg/mL). The obtained CC 50 (μg/mL) of S ebulus extract on THP1 macrophages and AMB was 30 000 and 1.9 μg/mL, respectively.
| Effects of extract on Leishmania promastigotes and IC 50 estimation
The antileishmanial effect of S ebulus aquatic extract was evaluated against promastigotes of L major in order to estimate the IC 50 values (Figure 2) . The results revealed that the extract significantly affected the promastigotes growth, and the IC 50 of the extract was effective at the concentration of 3500 μg/mL killing 50% of the parasites (Figure 2A) . PBS, as a negative control, had no effects on promastigotes of L major ( Figure 2B ). For AMB (tested at 1.1-3.1 μg/mL), as a positive reference control, 50% growth inhibition of L major was observed at the concentration of 1.2 μg/mL ( Figure 2C ).
| Parasite rescue and transformation assay and EC 50 estimation
Using the MTT test, the EC 50 (μg/mL) of S ebulus aquatic extract for amastigotes form of L major is shown in Figure 3 , which demonstrates that for L major amastigotes, the EC 50 of the extract was 6000 μg/mL ( Figure 3A) . PBS, as the negative control, had no effects on amastigotes of L major (Figure 3 B) . For AMB (positive control), the EC 50 of the extract was 2.6 μg/mL ( Figure 3C ). As the cytotoxicity (CC 50 ) results revealed, the CC 50 of PMA-treated human THP1 macrophages ( Figure 2A ) and the EC 50 of the S ebulus aquatic extract were 30 000 and 6000 μg/mL, respectively. This means that S ebulus extract was not only toxic to human THP1 cells, but also killed the L major amastigotes (Figures 2 and 3 ).
| Sambucus ebulus extract as a safe compound in BALB/c mice
The results of toxicity assay in BALB/c mice in Figure 4 indicated no evidence of toxicity in any of them after 7-day administration of F I G U R E 1 Cytotoxicity assay of different concentrations of Sambucus ebulus aqueous extract using PMA-treated human monocyte cell line (THP1) after 48 h via MTT assay (A) S ebulus extract is only toxic to cells at higher concentrations (30 000 μg/mL); (B) PBS; and (C) amphotericin B (AMB) was used as negative and positive reference controls, respectively. The data are reported here as mean ± SD of three repeated experiments with identical outcomes S ebulus extract. There were no considerable changes in the body weight suggesting no toxicity of the different concentrations of the extract. All of the mice across different groups (Table 1) elucidated normal behaviour and body weight as followed daily. There was no difference between treated and untreated groups.
| Lesion development in Leishmania major infected BALB/c mice treated with Sambucus ebulus extract
The footpad lesion development across all the infected mice with 
| Sambucus ebulus extract reduces the parasite burden in the lymph nodes of BALB/c mice
The Leishmania parasite burden in the lymph node of BALB/c mice was assessed using conventional limiting dilution assay (microtitration) ( Figure 6A ) and quantitative real-time PCR (qPCR) ( Figure 6B ), at 8 weeks after infection in all mice groups. As displayed in Figure 6A ,B, in G2 (AMB 8 mg/kg), G4 (SE 100 mg/kg, IM), respectively, compared with the other controls (G1 and G3) (P < 0
| Effects of Sambucus ebulus extract on cytokine production in mice
.01) ( Figure 7C ). The highest level of IL-4 production was found in G1
(no treatment), G3 (PBS) and G4 (SE 100 mg/kg, IM).
| High NO level and low ARG activity in groups treated with Sambucus ebulus extract
The vital amino acid, L-Arginine, is metabolized via iNOS or ARG based upon the important signals from the medium of macrophages.
Inside these cells, immune responses through Th1 cytokines (IFN-γ)
enhance the iNOS induction and NO production, while the Th2 cytokines (IL-4) promote the generation of ARG enzyme. 9, 35 Parasites clearance into macrophage cells and their survival are mediated through NO and ARG, respectively. 9 As presented in Figure 8A , all of the S ebulus extract concentrations including G4 (SE 100 mg/kg, IM), G5 (SE 150 mg/kg, IM), G6
(SE 200 mg/kg, IM), G7 (SE 100 mg/kg, IL), G8 (SE 150 mg/kg, IL), G9 (SE 200 mg/kg, IL) and G2 (AMB 8 mg/kg) significantly raised the level of NO production as an antileishmanial compound compared to the G1 (no treatment) and G3 (PBS), respectively. Intralesionally injected (IL) groups including G9 (SE 200 mg/kg, IL), G8 (SE 150 mg/ kg, IL) and G7 (SE 100 mg/kg, IL) had the highest NO production, respectively, compared to intramuscularly injected groups (IM) (P < 0.05). Among all groups treated with S ebulus extract, G9 (SE 200 mg/kg, IL) had the maximum rise in the NO level. This is in a direct correlation with the increased IFN-γ induction and the active cellular immunity (Th1) through intralesionally injected (IL) groups (G7, G8 and G9) ( Figure 8A ).
As we expected, ARG level was inversely reduced across all the S ebulus treated groups including G4, G5, G6, G7, G8, G9 and G2, respectively, when compared to the control groups (P < 0.05) ( Figure 8B) . As F I G U R E 5 Lesion development/ swelling of footpad in Leishmania major infected BALB/c mice before and after treatment with Sambucus ebulus (SE) aquatic extract. The lesion size was documented by a metric caliper through measuring the increase in footpad thickness/width from 1 to 10 wk after infection presented in Figure 8 , the data revealed a direct relationship between ARG level and NO production; when NO production was elevated, the ARG level diminished in the treated groups. Our data exhibited that G9 in the treated and G2 in control groups had the highest NO production, while G9 in the treated and G2 in control groups had the lowest ARG activity (Figure 8 ). According to the increasing production of NO and diminishing ARG activity, the cellular immune responses (Th1) were active through S ebulus extract treatment.
F I G U R E 6
Parasite burden in the lymph nodes of distinct mice groups after infection with Leishmania major and treatment with Sambucus ebulus (SE) aquatic extract at 8 wk postinfection; (A) conventional limiting dilution assay; and (B) quantitative real-time PCR (qPCR) through two administration routes including intralesional (IL) and intramuscular (IM) (*P < 0.05, **P < 0.01, ***P < 0.001) F I G U R E 7 Evaluation of cytokine production in the supernatant of frozen and thawed (F/T) antigen-stimulated splenocytes of Sambucus ebulus extract treated BALB/c mice groups compared to positive and negative controls; the cytokines including (A) IFN-γ, (B) IL-4 and (C) IFN-γ/IL-4 ratio were evaluated (*P < 0.05, **P < 0.01, ***P < 0.001) F I G U R E 8 Quantification of nitric oxide (NO) production and arginase (ARG) activity in the mice treated with different concentrations of Sambucus ebulus extract in the spleen and footpad of BALB/c mice, respectively (n = 5); (A) NO production (μmol/L) was quantified via Griess assay; (B) ARG activity (mU/mL) was measured by microplate method. (*P < 0.05, **P < 0.01, ***P < 0.001)
| D ISCUSS I ON
To date, there has been an urgent increasing need to find novel alternative natural drugs for the treatment of disfiguring cutaneous leishmaniasis capable of providing the best efficiency, high safety, low price and easy drug administration. 13 In addition, due to lack of effective vaccines, the only efficient tool for fighting the disease is antileishmanial drugs. 33 Therefore As mentioned earlier, S ebulus has been utilized as an important herbal drug in traditional medicine for the treatment of different diseases. 20, 40, 41 The various medicinal activities of Sambucus species have been previously described including anti-Helicobacter, 41 antibacterial, 42 antiviral, 43 anti-inflammatory 22 and radical scavenging 44 effects, as well as inhibitory effects of interleukin 1 (IL-1) and tumour necrosis factor-α (TNF-α). 22 Further, it has also shown a rapid wound healing activity. 20, 40 In order to confirm the antileishmanial activity of S ebulus extract, cytotoxicity (CC 50 ), inhibitory (IC 50 ) and effective (EC 50 ) concentration assessments were performed. In this work, the results suggested that the extract had a direct and strong action on both forms of L major promastigotes and amastigotes without adversely affecting the host macrophages. The best concentrations of the extract for reducing promastigotes and amastigotes growth were 3500 and 6000 μg/mL, respectively, killing 50% of both forms of the parasite. The exact mechanism of action by which S ebulus kills the Leishmania parasites has remained unclear. Shokrzadeh and colleagues have found that the S ebulus has anti-Helicobacter pylori activity. 20 There is strong evidence to suggest that the extract may inhibit the urease and growth of Helicobacter. The possible explanations for antileishmanial activity of S ebulus may involve rapid and intense wound healing activity of the S ebulus extract as well as inhibition of parasite urease pathway. 40 After in vitro assessment of S ebulus extract on L major, the aquatic extract was used as a safe therapeutic herbal drug in the parasite infected susceptible mice. We used three distinct S ebulus extract con- and maximum ARG activity are the signs of humoral immunity (Th2), in which the Leishmania parasite benefits from 49 and have negative regulatory effects on cytokines in the cell-mediated response (Th1).
Our results are in agreement with other studies. 49, 52, 53 The ratio of IFN-γ/IL-4 in splenocytes isolated from mice stimulated with Leishmania frozen and thawed treated with S ebulus extract was significantly higher than that of control groups (no treatment and PBS groups). Both IFN-γ (as a Th1 cytokine) and IL-4 (as a Th2 cytokine) inductions are utilized as main signatures of Th1 and Th2 immune responses, respectively. 49, 53 Our results support the findings of other studies demonstrating the induction of IL-4-driven Th2 immune responses, which have proven to boost nonhealing response in Leishmania infection. 53, 54 Notably, in both in vitro and in vivo studies, the antileishmanial activity of S ebulus extract was dose-dependent suggesting that with the rise in their concentrations, the effects of the extract were potentiated. This dose-dependent activity is in agreement with other studies. 55 In addition, in the current study, we administered two different treatment routes including intralesional (IL) and intramuscular (IM) for assessing the effects of S ebulus extract on mice infected with L major. Interestingly, our results indicated significant differences in the parasite load, IFN-γ/IL-4 ratio, NO production and ARG activity.
Intralesionally (IL) injected groups (G7, G8 and G9) had significantly smaller lesions compared with intramuscularly (IM) injected and control groups. One possible explanation for the inadequate responses to IM injected therapy of Leishmania infection in mice is that even low concentrations of the extract and AMB can reach the CL infection site. Our findings provide more evidence for the other studies. 56, 57 Altogether, our findings on in vitro assessment of CC 50 , IC 50 and EC 50 
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